CNS
IMS Disease Insights – Alzheimer’s disease: Primary research & evidence-based data
November 11 by Pharmaceuticals & Biotechnology EditorOf the nine major pharmaceutical markets (i.e., US, UK, France, Germany, Italy, Spain, Japan, China, Brazil), IMS Health forecasts that the Alzheimer’s disease market will grow from $5.7 billion in 20...
Innovative Therapies for Alzheimer’s Disease
September 26 by Pharmaceuticals & Biotechnology EditorIn the US alone, Alzheimer’s disease healthcare costs are projected to increase from $200 billion in 2013 to $1.2 trillion by 2050. Thus, the lack of good treatment options for AD creates a he...
Cutting Attrition Rates in Your CNS Clinical Trials
January 07 by Helen WinsorDr. Wolfgang Eglmeier, Head of Clinical Operations Germany, Grünenthal GmbH, joins Helen Winsor from Pharma IQ, to discuss optimising clinical development in CNS. He outlines the main challenges when...
Market for CNS Biomarkers Predicted to Grow to $3.2 Billion by 2015
December 02 by Pharma IQBiomarkers are now being used by a large number of companies in the biopharmaceutical industry - and one of the key therapeutic areas where they are utilised is in CNS drug development, wher...